Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2008 | Case report

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma

Authors: Jasmine YM Tang, Rajendra Singh Rampaul, Kwok L Cheung

Published in: World Journal of Surgical Oncology | Issue 1/2008

Abstract

Background

The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.

Case presentation

Herein we present two cases where fulvestrant, as the only available parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to provide a means to initiate treatment in those patients who present with varying degrees of intestinal obstruction.

Conclusion

Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical benefit with less toxicity, in appropriately selected patients.

Available only for authorised users

Robertson JF: Fulvestrant (Faslodex) how to make a good drug better. Oncologist. 2007, 12 (7): 774-784. 10.1634/theoncologist.12-7-774.CrossRefPubMed

Clavien P-A, Laffer U, Torhos J, Harder F: Gastrointestinal metastases as first clinical manifestation of the dissemination of a breast cancer. Eur J Surg Oncol. 1990, 16 (2): 121-126.PubMed

Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery. 1993, 114: 637-642.PubMed

Winston CB, Hadar O, Teitcher JB, Caravelli JF, Sklarin NT, Panicek DM, Liberman L: Metastatic Lobular Carcinoma of the Breast: Patterns of Spread in the Chest, Abdomen, and Pelvis on CT. AJR Am J Roentgenol. 2000, 175 (3): 795-800.CrossRefPubMed

Sastre-Garaux X, Jouve M, Asselain B, Vincent-Salomom A, Beuzeboc P: Infiltrating lobular carcinoma of the breast: clinicopatholgic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996, 77: 113-120. 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8.CrossRef

Piccart M, Parker LM, Pritchard KI: Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Annals of Oncology. 2003, 14: 1017-1025. 10.1093/annonc/mdg290.CrossRefPubMed

Babs GT, Hans P, Henk B: Clinical Presentation, Endoscopic Features and Treatment of Gastric Metastases from Breast Carcinoma. Cancer. 2000, 89: 2214-2221. 10.1002/1097-0142(20001201)89:11<2214::AID-CNCR9>3.0.CO;2-D.CrossRef

Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Weyngaert Van Den D, Becquart D, Borms M, Cocquyt V, Broecke Van Den R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I: Fulvestrant (Faslodex mark) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat. 2008, 109: 59-65. 10.1007/s10549-007-9628-2.CrossRefPubMed

Mauriac L, Pippen JE, Albano JQ, Gertlerd SZ, Osborne CK: Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003, 39: 1228-1233. 10.1016/S0959-8049(03)00199-0.CrossRefPubMed

10.

Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology. 2002, 20: 3396-3403. 10.1200/JCO.2002.10.057.CrossRefPubMed

11.

Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: A double-bline, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North Americal trial. Journal of Clinical Oncology. 2002, 20: 3386-3395. 10.1200/JCO.2002.10.058.CrossRefPubMed

12.

Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK: Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated with Endocrine Therapy: A Multinational, Double-Bline, Randomized Trial. Journal of Clinical Oncology. 2004, 22: 1605-1613. 10.1200/JCO.2004.02.112.CrossRefPubMed

Title: The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma
Authors: Jasmine YM Tang
Rajendra Singh Rampaul
Kwok L Cheung
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2008
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-6-128

At a glance: The STEP trials

Springer Medicine

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma

Abstract

Background

Case presentation

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Post-traumatic soft tissue tumors: Case report and review of the literature a propos a Post-traumatic paraspinal desmoid tumor

Advantage of vacuum assisted closure on healing of wound associated with omentoplasty after abdominoperineal excision: a case report

Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy

Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma

Erratum to: Thyroid cancer causing obstruction of the great veins in the neck

Delayed malignant melanoma recurrence simulating primary ovarian cancer: Case report